Regenerative Treatment of Liver Cirrhosis Using Allogeneic Adipose-Derived Mesenchymal Stem Cells: A Case Report

Technical Summary: Regenerative Treatment of Liver Cirrhosis Using Allogeneic Adipose-Derived Mesenchymal Stem Cells

Problem Statement
End-stage liver cirrhosis and chronic liver failure represent life-threatening, irreversible conditions characterized by hepatocellular dysfunction, fibrosis, and impaired regenerative capacity. While liver transplantation remains the most effective therapy, its application is severely constrained by donor scarcity, high costs, surgical risks, and the necessity for lifelong immunosuppression. Current supportive management strategies (e.g., antibiotics, vasopressors, artificial liver support systems) improve clinical parameters but fail to significantly alter long-term survival or disease prognosis. Consequently, there is a critical unmet medical need for alternative therapeutic strategies that can promote hepatic regeneration and restore liver function without the limitations of transplantation.

Methodology
This study presents a single case report of a 69-year-old male with chronic liver cirrhosis and portal hypertension, diagnosed in 2012, who was treated with a regenerative protocol using allogeneic adipose-derived mesenchymal stem cells (AT-MSCs).

• Cell Preparation: Human allogeneic AT-MSCs were isolated from the stromal vascular fraction of healthy donor adipose tissue obtained via lipoaspiration. Donors were rigorously screened for infectious diseases (HIV, HBV, HCV, etc.). Cells were isolated using enzymatic digestion (collagenase type I), expanded in DMEM/F12 medium with fetal bovine serum, and passaged up to passage three (P3) under Good Manufacturing Practice (GMP) compliance. Cells were cryopreserved and thawed prior to administration.
• Treatment Protocol: The patient received a total of 160 million viable allogeneic AT-MSCs administered via intravenous (IV) infusion. The regimen consisted of three initial doses of 50 million cells each (June 2024, July 2024, October 2024) and a booster dose of 10 million cells in December 2025.
• Monitoring: Clinical status and biochemical markers were monitored monthly over a one-year period. Assessments focused on symptoms (fatigue, appetite, energy), liver enzymes (SGOT, SGPT), bilirubin levels, coagulation profiles, and signs of disease progression (ascites, variceal bleeding, hepatic encephalopathy).

Key Results
Following the treatment protocol, the patient demonstrated significant clinical stabilization and biochemical improvement:

• Biochemical Markers: Liver enzymes normalized, with SGOT decreasing from a baseline of 94.6 U/L to 17.4 U/L and SGPT from 32.9 U/L to 10.2 U/L by December 2025. Bilirubin levels remained within normal ranges throughout.
• Clinical Symptoms: The patient reported marked improvements in fatigue, weakness, and appetite. By the end of the treatment period, the patient described feeling "much lighter and more energetic."
• Safety and Progression: No adverse events, infusion-related complications, or signs of acute hepatic decompensation were observed. Follow-up assessments indicated no new occurrences of gastrointestinal bleeding, ascites, or hepatic encephalopathy. While imaging continued to show morphological characteristics of cirrhosis, there were no radiological signs of further disease progression.

Key Contributions

• Clinical Evidence: This report provides clinical data on the safety and efficacy of intravenously administered allogeneic AT-MSCs in a patient with advanced liver cirrhosis, a population where clinical data on allogeneic AT-MSCs remains limited compared to autologous therapies.
• Therapeutic Alternative: The study demonstrates that AT-MSC therapy can serve as a viable alternative or bridging therapy for patients who are not candidates for or are reluctant to undergo liver transplantation.
• Mechanistic Insight: The paper reinforces the hypothesis that the therapeutic effects of AT-MSCs are primarily driven by paracrine mechanisms (secretion of soluble factors, growth factors, and exosomes) rather than direct differentiation into hepatocytes. These factors are suggested to modulate inflammation, inhibit hepatic stellate cell activation, and promote tissue repair.

Significance and Claims
The authors claim that allogeneic AT-MSC therapy is a safe and effective intervention for enhancing the clinical status of patients with advanced liver cirrhosis. The study suggests that this approach addresses the critical gap in current treatment options by offering a less invasive, potentially cost-effective method to stabilize liver function and improve quality of life.

However, the paper maintains a modest tone regarding the underlying mechanisms, acknowledging that the precise therapeutic pathways remain inadequately understood. The authors emphasize that while the observed clinical stabilization and biochemical normalization are promising, the findings are based on a single case. They conclude that further extensive long-term case-control studies and randomized controlled trials are necessary to validate the complete therapeutic efficacy, determine optimal dosing, and fully elucidate the mechanisms of action before AT-MSCs can be widely adopted as a standard treatment for liver cirrhosis.